Lyra Therapeutics Inc
NASDAQ:LYRA
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
US |
Lyra Therapeutics Inc
NASDAQ:LYRA
|
21.7m USD | 0 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -164 697 976 | |
US |
Eli Lilly and Co
NYSE:LLY
|
737.5B USD | 26.4 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 19.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 1 026 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
368.4B USD | 6.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.1B USD | 7.8 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
187.6B GBP | 61.4 | ||
CH |
Roche Holding AG
SIX:ROG
|
188.4B CHF | 4.7 | ||
CH |
Novartis AG
SIX:NOVN
|
181.2B CHF | 4.8 | ||
US |
Pfizer Inc
NYSE:PFE
|
162.7B USD | 5.7 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.